BC
ANIK icon

Bartlett & Co’s Anika Therapeutics ANIK Stock Holding History

Bartlett & Co’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-80
Closed -$3K – 716
2014
Q4 		$3K Buy
+80
New +$3.13K ﹤0.01% 739

Other funds holding ANIK

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
LCP
Lombardia Capital Partners Pasadena, California $110M AUM 13.11% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.7B AUM 6.69% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

Bartlett & Co's ANIK Position: Q1 2015 in Review

Bartlett & Co sold out of Anika Therapeutics (ANIK) in Q1 2015, closing a stake of 80 shares — an estimated $3K sold.

Bartlett & Co first reported a position in ANIK in Q4 2014 and held it in 1 quarter. The position peaked at $3K in Q4 2014. 159 funds tracked by Wall St. Rank hold ANIK as of Q1 2015.

  • Bartlett & Co reported no remaining Anika Therapeutics position as of Q1 2015 after selling out during the quarter.
  • Bartlett & Co sold 80 Anika Therapeutics shares in Q1 2015, an estimated $3K.
  • Bartlett & Co first reported a position in Anika Therapeutics in Q4 2014 and held it in 1 quarter.
  • Bartlett & Co's Anika Therapeutics position peaked at $3K in Q4 2014.
  • 159 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2015.

Based on Bartlett & Co's 13F filing for Q1 2015, filed 1 May 2015.